Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing
Strategic Profile
As a well-positioned sole European supplier, Vistin holds a defensible market position with exclusive geographic focus. The company maintains a strong balance sheet with an 81% equity ratio and net cash position. Revenue grew 44% year-over-year to NOK 438 million in 2023, demonstrating robust market demand for diabetes treatments.
Cyborg Score Rationale
Vistin benefits from a unique market position as Europe's sole dedicated Metformin producer in a growing diabetes treatment market. Strong financial fundamentals with 81% equity ratio and consistent revenue growth support operational stability. Capacity expansion and ISO 14001 certification demonstrate commitment to sustainable growth.
Top Insights
Monopoly-like position as Europe's only dedicated Metformin HCl manufacturer serving international pharma companies
Significant capacity expansion underway targeting >7000 MT/year to meet rising Type 2 diabetes treatment demand
Strong financial performance: 44% revenue growth (2023) with healthy EBITDA margins and net cash position
Recent board governance changes (May 2025) with chairman Øyvin Brøymer consolidating stake to 44.35% ownership
Named Competitors
Metformin Hydrochloride API — Global Metformin producers based primarily in China and India
Recent Developments
(June 2025) Dividend payment of NOK 1.25 per share approved at AGM
(May 2025) Board member Øystein Stray Spetalen withdrew from re-election; Chairman Brøymer increased shareholding to 44.35%